Document Detail


Tellimagrandin I enhances gap junctional communication and attenuates the tumor phenotype of human cervical carcinoma HeLa cells in vitro.
MedLine Citation:
PMID:  16338066     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Tellimagrandin I and chebulinic acid, two hydrolysable tannins, have been shown to exert anti-tumor properties. Dysfunctional gap junctional communication (GJIC) has been recognized as being involved in carcinogenesis. The human cervical carcinoma HeLa cells have been reported to be deficient in functional GJIC. In present study, we investigated whether tellimagrandin I and chebulinic acid might restore functional GJIC in HeLa cells. Both compounds could inhibit the growth of HeLa cells. Either Lucifer yellow transfer assay or calcein transfer assay demonstrated that tellimagrandin I improved GJIC in HeLa cells while chebulinic acid showed no effect on GJIC. The GJIC enhancement by tellimagrandin I occurred along with an increase of Cx43 gene expression at mRNA and protein levels. Exposure to tellimagrandin I also led to inhibition of proliferation and anchorage-independent growth of HeLa cells. In addition, tellimagrandin I decreased the percentage of cells in the G0/G1 and G2/M phases coinciding with an increase in the percentage of cells in the S phase. The accumulation of cells in S phase was coupled with a decreased expression of cyclin A that was critical to the progression of S phase. These results suggested that restoring GJIC might be one explanation for tellimagrandin I antitumor effects, whereas chebulinic acid exerted antitumor action through other pathways.
Authors:
Zong-Chun Yi; Yan-Ze Liu; Hai-Xia Li; Yan Yin; Feng-Yuan Zhuang; Yu-Bo Fan; Zhao Wang
Related Documents :
19625766 - Reprogramming of hela cells upon dnmt3l overexpression mimics carcinogenesis.
22397586 - Quantitative changes in intracellular calcium and extracellular-regulated kinase activa...
6368146 - What determines the degradation rate of an injected protein?
10665656 - Cisplatin-resistant hela cells are resistant to apoptosis via p53-dependent and -indepe...
8518056 - Risk of thrombosis in human atherosclerotic plaques: role of extracellular lipid, macro...
18023406 - A cytolytic assay for the measurement of palytoxin based on a cultured monolayer cell l...
Publication Detail:
Type:  In Vitro; Journal Article; Research Support, Non-U.S. Gov't     Date:  2005-12-09
Journal Detail:
Title:  Cancer letters     Volume:  242     ISSN:  0304-3835     ISO Abbreviation:  Cancer Lett.     Publication Date:  2006 Oct 
Date Detail:
Created Date:  2006-10-09     Completed Date:  2006-12-08     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  7600053     Medline TA:  Cancer Lett     Country:  Ireland    
Other Details:
Languages:  eng     Pagination:  77-87     Citation Subset:  IM    
Affiliation:
Department of Biological Sciences and Biotechnology, Tsinghua University, Beijing 100084, China. yizc@buaa.edu.cn
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Antineoplastic Agents / pharmacology
Connexin 43 / biosynthesis
Disease Progression
Dose-Response Relationship, Drug
Drugs, Chinese Herbal / therapeutic use
Female
Fluoresceins / metabolism
Gallic Acid / analogs & derivatives*,  pharmacology
Gap Junctions*
Gene Expression Regulation, Neoplastic*
Glucosides / pharmacology*
Hela Cells
Humans
Hydrolyzable Tannins / pharmacology
Isoquinolines / pharmacology
Phenotype
Uterine Cervical Neoplasms / drug therapy*,  pathology*
Chemical
Reg. No./Substance:
0/Antineoplastic Agents; 0/Connexin 43; 0/Drugs, Chinese Herbal; 0/Fluoresceins; 0/Glucosides; 0/Hydrolyzable Tannins; 0/Isoquinolines; 1461-15-0/fluorexon; 149-91-7/Gallic Acid; 18942-26-2/chebulinic acid; 77944-88-8/lucifer yellow; 79786-08-6/tellimagrandin I

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Aurora-A overexpression associates with Ha-ras codon-12 mutation and blackfoot disease endemic area ...
Next Document:  Dok1 expression and mutation in Burkitt's lymphoma cell lines.